Freeline Therapeutics Holdings PLC ADR (FRLN): Price and Financial Metrics
GET POWR RATINGS... FREE!
FRLN Stock Price Chart Interactive Chart >
FRLN Price/Volume Stats
|Current price||$0.60||52-week high||$1.29|
|Prev. close||$0.61||52-week low||$0.46|
|Day high||$0.62||Avg. volume||142,894|
|50-day MA||$0.56||Dividend yield||N/A|
|200-day MA||$0.75||Market Cap||38.83M|
Freeline Therapeutics Holdings PLC ADR (FRLN) Company Bio
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.
Most Popular Stories View All
FRLN Latest News Stream
|Loading, please wait...|
FRLN Latest Social Stream
View Full FRLN Social Stream
Latest FRLN News From Around the Web
Below are the latest news stories about FREELINE THERAPEUTICS HOLDINGS PLC that investors may wish to consider to help them evaluate FRLN as an investment opportunity.
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in MARVEL-1 Phase 1/2 clinical trial LONDON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a
LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30, 2022. The Company will continue to trade
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has decided to focus its resources on FLT201 in Gaucher disease and FLT190 in Fabry disease. The company will stop investment in further development of FLT180a without a partner. Additionally, Freeline announced updated data from the two patients treated in the first cohort from the MARVEL-1 Phase 1/2 trial of FLT190 at a dose of 7.5e11 vg/kg. People with classic Fabry disease have little to no functional α-Gal A enzyme. Data exhibited elevated α
FRLN Price Returns